Published March 17, 2025 | Version v1
Journal article Open

Cost-effectiveness analysis and medication use for gangrene treatment in type 2 diabetes patients: A systematic literature review

Authors/Creators

  • 1. Universitas Bhakti Kencana, Bandung, Indonesia
  • 2. Universitas Islam Bandung, Bandung, Indonesia

Description

This systematic literature review assesses the cost-effectiveness and medication use in treating gangrene among patients with type 2 diabetes mellitus (T2DM). The review focuses on evaluating different treatment regimens and identifying key factors that influence cost-effectiveness outcomes. A total of 22 studies were analyzed to understand regional variations in treatment approaches and the cost-effectiveness of medications, including empagliflozin, semaglutide, and TLC-NOSF dressings, among others. The methodology involved a comprehensive search of databases for relevant studies published between 2019 and 2024. The search terms were selected based on the population, intervention, comparison, and outcomes (PICO) framework, with keywords such as "type 2 diabetes mellitus," "gangrene," "foot ulcers," and "cost-effectiveness," followed by an in-depth analysis using VOSviewer to map keyword trends and relationships. The search terms were selected based on the population, intervention, comparison, and outcomes (PICO) framework, with keywords such as "type 2 diabetes mellitus," "gangrene," "foot ulcers," and "cost-effectiveness.". The studies were evaluated based on their design, population characteristics, interventions, outcomes, and economic impact. The results showed significant geographic variations, with higher cost-effectiveness reported in developed countries due to better access to advanced treatments. Medications like empagliflozin and semaglutide consistently demonstrated superior cost-effectiveness, particularly in managing cardiovascular complications in high-risk T2DM patients. Patient adherence was also identified as a crucial factor in improving long-term clinical outcomes and reducing healthcare costs. In conclusion, this review highlights the importance of cost-effective treatments and patient adherence in managing gangrene in T2DM patients. Access to innovative medications and support for adherence are essential for optimizing both clinical outcomes and economic sustainability.

Files

PHAR_article_144858.pdf

Files (1.0 MB)

Name Size Download all
md5:cf8b19486daa185eb95fb86aab2ef126
840.6 kB Preview Download
md5:64c6a3792b9e4b1a6e3e77cee80a8cce
207.2 kB Preview Download

Additional details

Cites
Publication: 10.1016/j.dsx.2014.04.004 (DOI)
Publication: 10.1016/j.jsps.2024.102057 (DOI)
Publication: 10.1177/0300060513483391 (DOI)
Publication: 10.1007/s13300-019-00736-6 (DOI)
Publication: 10.1007/bf03320526 (DOI)
Publication: 10.1212/WNL.0000000000013313 (DOI)
Publication: 10.1007/s41669-019-0171-y (DOI)
Publication: 10.1007/s13300-021-01040-y (DOI)
Publication: 10.1136/bcr-2020-237784 (DOI)
Publication: 10.1371/journal.pone.0191953 (DOI)
Publication: 10.1371/journal.pone.0244851 (DOI)
Publication: 10.1007/s13300-019-0630-6 (DOI)
Publication: 10.1111/iwj.13591 (DOI)
Publication: 10.52711/0974-360X.2021.00494 (DOI)
Publication: 10.1136/bmjdrc-2019-000705 (DOI)
Publication: 10.1186/s12962-019-0180-9 (DOI)
Publication: 10.3389/fendo.2021.684960 (DOI)
Publication: 10.1016/j.ijscr.2020.11.037 (DOI)
Publication: 10.12968/jowc.2019.28.12.808 (DOI)
Publication: 10.1186/s13098-022-00801-4 (DOI)
Publication: 10.1007/s12325-020-01464-1 (DOI)
Publication: 10.1007/s13300-021-01159-y (DOI)
Publication: 10.3393/AC.2020.06.22 (DOI)
Publication: 10.1136/bmj.n71 (DOI)
Publication: 10.1186/s12962-021-00299-z (DOI)
Publication: 10.1111/dom.14625 (DOI)
Publication: 10.1007/s00105-020-04699-9 (DOI)
Publication: 10.1590/0102-311X00036619 (DOI)
Publication: 10.1186/s13561-022-00377-9 (DOI)
Publication: 10.1007/s13300-022-01300-5 (DOI)
Publication: 10.2337/dci20-0017 (DOI)
Publication: 10.3390/ijerph20010187 (DOI)
Publication: 10.1001/jamanetworkopen.2022.50639 (DOI)
Publication: 10.2217/pme-2023-0017 (DOI)
Publication: 10.1111/dom.13564 (DOI)
Publication: 10.1016/j.jcjd.2021.07.001 (DOI)
Has part
Figure: 10.3897/pharmacia.72.e144858.figure2 (DOI)
Figure: 10.3897/pharmacia.72.e144858.figure1 (DOI)
Figure: 10.3897/pharmacia.72.e144858.figure3 (DOI)

References

  • Ahmed AA, Algamdi SA, Alzahrani AM (2015) Surveillance of risk factors for diabetic foot ulceration with particular concern to local practice. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 9: 310–315. https://doi.org/10.1016/j.dsx.2014.04.004
  • AlRuthia Y, Hani Aburisheh K, Ata S, Bin Salleeh R, Alqudhibi SB, Alqudhibi RB, Alkraidis Z, Humood Alkhalaf H, Abdullah Almogirah A, Mujammami M, Al Khalifah R (2024) Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia. Saudi Pharmaceutical Journal 32: 102057. https://doi.org/10.1016/j.jsps.2024.102057
  • Alzahrani H, Bedir Y, Al-Hayani A (2013) Efficacy of shellac, a natural product, for the prevention of wet gangrene. Journal of International Medical Research 41: 795–803. https://doi.org/10.1177/0300060513483391
  • Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B, Hunt B, Capehorn M (2020) Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: Long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Therapy 11: 259–277. https://doi.org/10.1007/s13300-019-00736-6
  • Baio G, Russo P (2010) A decision-theoretic framework for the application of cost-effectiveness analysis in regulatory processes. PharmacoEconomics – Italian Research Articles 12: 5–16. https://doi.org/10.1007/bf03320526
  • Campbell JD, Whittington MD, Pearson SD (2022) Performing cost-effectiveness analyses to support policy making: Key lessons from the assessment of aducanumab. Neurology 98: 360–365. https://doi.org/10.1212/WNL.0000000000013313
  • Capel M, Ciudin A, Mareque M, Rodríguez-Rincón RM, Simón S, Oyagüez I (2020) Cost-effectiveness analysis of exenatide versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus. PharmacoEconomics – Open 4: 277–286. https://doi.org/10.1007/s41669-019-0171-y
  • Ehlers LH, Lamotte M, Monteiro S, Sandgaard S, Holmgaard P, Frary EC, Ejskjaer N (2021) The Cost-effectiveness of empagliflozin versus liraglutide treatment in people with type 2 diabetes and established cardiovascular disease. Diabetes Therapy 12: 1523–1534. https://doi.org/10.1007/s13300-021-01040-y
  • Elbeddini A, Tayefehchamani Y, Davey M, Gallinger J, Hooda N, Aly A, Erickson D, Lee S (2021) Fournier's gangrene with dapagliflozin in a rural hospital: A case report. BMJ Case Reports 14. https://doi.org/10.1136/bcr-2020-237784
  • Ericsson Å, Glah D, Lorenzi M, Jansen JP, Fridhammar A (2018) Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLoS ONE 13: 1–16. https://doi.org/10.1371/journal.pone.0191953
  • Ezeofor VS, Bray N, Bryning L, Hashmi F, Hoel H, Parker D, Edwards RT (2021) Economic model to examine the cost-effectiveness of FlowOx home therapy compared to standard care in patients with peripheral artery disease. PLoS ONE 16(1): e0244851. https://doi.org/10.1371/journal.pone.0244851
  • Gæde P, Johansen P, Tikkanen CK, Pollock RF, Hunt B, Malkin SJP (2019) Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: A cost-effectiveness analysis in the Danish setting. Diabetes Therapy 10: 1297–1317. https://doi.org/10.1007/s13300-019-0630-6
  • Guest JF, Atkin L, Aitkins C (2021) Potential cost-effectiveness of using adjunctive dehydrated human amnion/chorion membrane allograft in the management of non-healing diabetic foot ulcers in the United Kingdom. International Wound Journal 18: 889–901. https://doi.org/10.1111/iwj.13591
  • Holidah D, Dewi IP, Christianty FM, Muhammadiy NS, Huda N (2021) Antidiabetic and antidyslipidemic activity of secang (Caesalpinia sappan L.) wood extract on diabetic rat. Research Journal of Pharmacy and Technology 14: 2801–2806. https://doi.org/10.52711/0974-360X.2021.00494
  • Hunt B, Malkin SJP, Moes RGJ, Huisman EL, Vandebrouck T, Wolffenbuttel B (2019) Once-weekly semaglutide for patients with type 2 diabetes: A cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Research and Care 7: 1–9. https://doi.org/10.1136/bmjdrc-2019-000705
  • Izadi M, Joneidi Jafari N, Hosseini MS, Saafaat O (2017) Therapeutic effects of ozone in patients with diabetic foot ulcers: Review of the literature. Biomedical Research (India) 28: 7846–7850.
  • Lau E, Salem A, Chan JCN, So WY, Kong A, Lamotte M, Luk A (2019) Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: A cost-effectiveness analysis. Cost Effectiveness and Resource Allocation 17: 1–13. https://doi.org/10.1186/s12962-019-0180-9
  • Lin WQ, Cai ZJ, Chen T, Liu MB, Li N, Zheng B (2021) Cost-effectiveness of dipeptidylpeptidase-4 inhibitors added to metformin in patients with type 2 diabetes in China. Frontiers in Endocrinology 12: 1–9. https://doi.org/10.3389/fendo.2021.684960
  • Lindsay PJ, Gibson LE, Bittner EA, Berg S, Chang MG (2020) Sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis complicating the perioperative management of a patient with type 2 diabetes mellitus (T2DM) and Fournier's gangrene: A case report. International Journal of Surgery Case Reports 77: 463–466. https://doi.org/10.1016/j.ijscr.2020.11.037
  • Lobmann R, Augustin M, Lawall H, Tigges W, Potempa C, Thiem H, Fietz C, Rychlik RPT (2019) Cost-effectiveness of TLC-sucrose octasulfate versus control dressings in the treatment of diabetic foot ulcers. Journal of Wound Care 28(12): 808–816. https://doi.org/10.12968/jowc.2019.28.12.808
  • Malkin SJP, Carvalho D, Costa C, Conde V, Hunt B (2022) The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetology and Metabolic Syndrome 14: 1–14. https://doi.org/10.1186/s13098-022-00801-4
  • Martín V, Vidal J, Malkin SJP, Hallén N, Hunt B (2020) Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide and sitagliptin in the Spanish setting. Advances in Therapy 37: 4427–4445. https://doi.org/10.1007/s12325-020-01464-1
  • McCrimmon RJ, Falla E, Sha JZ, Alsaleh AJO, Lew E, Hudson R, Baxter M, Palmer K (2021) Cost-effectiveness of iGlarLixi in people with type 2 diabetes mellitus suboptimally controlled on basal insulin plus metformin in the UK. Diabetes Therapy 12: 3217–3230. https://doi.org/10.1007/s13300-021-01159-y
  • Moon JY, Lee MR, Kim JH, Ha GW (2021) Fournier gangrene in a patient with type 2 diabetes mellitus treated with dapagliflozin: A case report. Annals of Coloproctology 37: S48–S50. https://doi.org/10.3393/AC.2020.06.22
  • Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Moher D (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71. https://doi.org/10.1136/bmj.n71
  • Ramos M, Men P, Wang X, Ustyugova A, Lamotte M (2021) Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Effectiveness and Resource Allocation 19: 1–11. https://doi.org/10.1186/s12962-021-00299-z
  • Reifsnider OS, Pimple P, Brand S, Bergrath Washington E, Shetty S, Desai NR (2022) Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States. Diabetes, Obesity and Metabolism 24: 652–661. https://doi.org/10.1111/dom.14625
  • Riedel U, Schüßler E, Härtel D, Keiler A, Nestoris S, Stege H (2020) Wound treatment in diabetes patients and diabetic foot ulcers. Hautarzt 71: 835–842. https://doi.org/10.1007/s00105-020-04699-9
  • Rodrigues JPV, de Souza Cazarim M, Chachá SGF, de Lourdes Candolo Martinelli A, Pereira LRL (2020) Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C. Cadernos de Saude Publica 36(2). https://doi.org/10.1590/0102-311X00036619
  • Shahtaheri RS, Bayazidi Y, Davari M, Kebriaeezadeh A, Yousefi S, Hezaveh AM, Sadeghi A, aL Lami AHM, Abbasian H (2022) Long-term cost-effectiveness of quality of diabetes care; experiences from private and public diabetes centers in Iran. Health Economics Review 12: 1–7. https://doi.org/10.1186/s13561-022-00377-9
  • Shao H, Alsaleh AJO, Dex T, Lew E, Fonseca V (2022) Cost-effectiveness of iGlarLixi versus premix BIAsp 30 in people with tType 2 diabetes suboptimally controlled by basal insulin in the US. Diabetes Therapy 13: 1659–1670. https://doi.org/10.1007/s13300-022-01300-5
  • Siegel KR, Ali MK, Zhou X, Ng BP, Jawanda S, Proia K, Zhang X, Gregg EW, Albright AL, Zhang P (2020) Cost-effectiveness of interventions to manage diabetes: Has the evidence changed since 2008? Diabetes Care 43: 1557–1592. https://doi.org/10.2337/dci20-0017
  • Stancu B, Ilyés T, Farcas M, Coman HF, Chiș BA, Andercou OA (2023) Diabetic foot complications: A retrospective cohort study. International Journal of Environmental Research and Public Health 20(1): 187. https://doi.org/10.3390/ijerph20010187
  • Su H-Y, Yang C-Y, Ou H-T, Chen S-G, Chen J-C, Ho H-J, Kuo S (2023) Cost-effectiveness of novel macrophage-regulating treatment for wound healing in patients with diabetic foot ulcers from the Taiwan health care sector perspective. JAMA Network Open 6: E2250639. https://doi.org/10.1001/jamanetworkopen.2022.50639
  • Szilberhorn L, Zelei T, Vellekoop H, Huygens S, Versteegh M, Mölken MR Van, Koleva-Kolarova R, Tsiachristas A, Wordsworth S, Nagy B (2023) Cost-effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries. Personalized Medicine 20: 387–399. https://doi.org/10.2217/pme-2023-0017
  • Viljoen A, Hoxer CS, Johansen P, Malkin S, Hunt B, Bain SC (2019) Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes, Obesity and Metabolism 21: 611–621. https://doi.org/10.1111/dom.13564
  • Wen J, Jin X, Al Sayah F, Johnson JA, Paulden M, Ohinmaa A (2022) Economic evaluation of sucrose octasulfate dressing for treatment of diabetic foot ulcers in patients with type 2 diabetes. Canadian Journal of Diabetes 46: 126–133. https://doi.org/10.1016/j.jcjd.2021.07.001